Literature DB >> 10337378

Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.

M A Bookman1.   

Abstract

Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug-resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum-free interval and optimize subsequent retreatment with platinum.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10337378

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  28 in total

1.  The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Authors:  Hagen Sjard Bachmann; Werner Meier; Andreas du Bois; Rainer Kimmig; Jan Dominik Kuhlmann; Winfried Siffert; Jalid Sehouli; Kerstin Wollschlaeger; Jens Huober; Peter Hillemanns; Alexander Burges; Barbara Schmalfeldt; Behnaz Aminossadati; Pauline Wimberger
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

2.  Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Authors:  Kathleen N Moore; Lainie P Martin; David M O'Malley; Ursula A Matulonis; Jason A Konner; Raymond P Perez; Todd M Bauer; Rodrigo Ruiz-Soto; Michael J Birrer
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

3.  Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Christopher Poon; Xiaopin Duan; Christina Chan; Wenbo Han; Wenbin Lin
Journal:  Mol Pharm       Date:  2016-10-21       Impact factor: 4.939

4.  Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.

Authors:  Kevin H Eng; Bret M Hanlon; William H Bradley; J Brian Szender
Journal:  Gynecol Oncol       Date:  2015-09-14       Impact factor: 5.482

5.  Cell fate regulation by gelsolin in human gynecologic cancers.

Authors:  Mohammad R Abedini; Pei-Wen Wang; Yu-Fang Huang; Mingju Cao; Cheng-Yang Chou; Dar-Bin Shieh; Benjamin K Tsang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

6.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Authors:  Britta Weigelt; Iñaki Comino-Méndez; Ino de Bruijn; Lei Tian; Jane L Meisel; Isaac García-Murillas; Charlotte Fribbens; Ros Cutts; Luciano G Martelotto; Charlotte K Y Ng; Raymond S Lim; Pier Selenica; Salvatore Piscuoglio; Carol Aghajanian; Larry Norton; Rajmohan Murali; David M Hyman; Laetitia Borsu; Maria E Arcila; Jason Konner; Jorge S Reis-Filho; Roger A Greenberg; Mark E Robson; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

7.  Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Kathleen N Moore; David Tritchler; Kenneth M Kaufman; Heather Lankes; Michael C J Quinn; Linda Van Le; Andrew Berchuck; Floor J Backes; Krishnansu S Tewari; Roger B Lee; Joshua P Kesterson; Robert M Wenham; Deborah K Armstrong; Thomas C Krivak; Michael A Bookman; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2017-09-19       Impact factor: 5.482

Review 8.  Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

Authors:  P A Vasey
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

9.  Predicting Ovarian Cancer Patients' Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures.

Authors:  Kun-Hsing Yu; Douglas A Levine; Hui Zhang; Daniel W Chan; Zhen Zhang; Michael Snyder
Journal:  J Proteome Res       Date:  2016-07-08       Impact factor: 4.466

10.  Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer.

Authors:  David Jacobson; Kathleen Moore; Camille Gunderson; Michelle Rowland; Rita Austin; Tanvi Prasad Honap; Jiawu Xu; Christina Warinner; Krithivasan Sankaranarayanan; Cecil M Lewis
Journal:  PeerJ       Date:  2021-06-17       Impact factor: 2.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.